PMID- 17344278
OWN - NLM
STAT- MEDLINE
DCOM- 20070918
LR  - 20220321
IS  - 0017-5749 (Print)
IS  - 1468-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 56
IP  - 9
DP  - 2007 Sep
TI  - Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary 
      haemochromatosis.
PG  - 1291-5
AB  - BACKGROUND AND AIMS: During the long-term treatment of patients with hereditary 
      haemochromatosis (HH) the authors observed that proton pump inhibitors (PPI) 
      reduced the requirement for maintenance phlebotomy. Gastric acid plays a crucial 
      role in non-haem iron absorption and the authors performed a case review and 
      intervention study to investigate if PPI-induced suppression of gastric acid 
      would reduce dietary iron absorption in C282Y homozygous patients. METHODS: 
      Phlebotomy requirements to keep serum ferritin approximately 50 microg/l before 
      (mean 6.1 (SE 0.6) years) and during (3.8 (0.9) years) administration of a PPI 
      were evaluated in seven patients and a post-prandial study was performed to 
      determine whether PPIs reduce absorption of non-haem iron (14.5 mg) from a test 
      meal in a further 14 phlebotomised patients with normal iron stores. RESULTS: 
      There was a significant reduction (p<0.001) in the volume of blood removed 
      annually before (2.5 (0.25) l) and while taking (0.5 (0.25) l) a PPI. 
      Administration of a PPI for 7d suppressed absorption of non-haem iron from the 
      meal as shown by a significant reduction (all p<0.01) in: area under the serum 
      curve (2145 (374) versus 1059 (219)), % recovery of administered iron at peak 
      serum iron (20.5 (3.2) versus 11.0 (2.0)%) and peak serum iron (13.6 (2.4) vs 6.1 
      (1.2) micromol/l) (all values are before vs during PPI). CONCLUSIONS: 
      Administration of a PPI to patients with HH can inhibit the absorption of 
      non-haem iron from a test meal and the habitual diet.
FAU - Hutchinson, Carol
AU  - Hutchinson C
AD  - The Iron Metabolism Interdisciplinary Research Group, King's College London, 
      London, UK.
FAU - Geissler, Catherine A
AU  - Geissler CA
FAU - Powell, Jonathan J
AU  - Powell JJ
FAU - Bomford, Adrian
AU  - Bomford A
LA  - eng
GR  - MC_U105960399/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20070307
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Iron, Dietary)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 9007-73-2 (Ferritins)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use
MH  - Enzyme Inhibitors/*therapeutic use
MH  - Ferritins/blood
MH  - Gastric Acid/metabolism
MH  - Hemochromatosis/drug therapy/*genetics/metabolism
MH  - Humans
MH  - Intestinal Absorption/drug effects
MH  - Iron, Dietary/blood/*pharmacokinetics
MH  - Lansoprazole
MH  - Middle Aged
MH  - Omeprazole/therapeutic use
MH  - Phlebotomy
MH  - Postprandial Period
MH  - *Proton Pump Inhibitors
PMC - PMC1954964
COIS- Competing interests: None.
EDAT- 2007/03/09 09:00
MHDA- 2007/09/19 09:00
PMCR- 2010/09/01
CRDT- 2007/03/09 09:00
PHST- 2007/03/09 09:00 [pubmed]
PHST- 2007/09/19 09:00 [medline]
PHST- 2007/03/09 09:00 [entrez]
PHST- 2010/09/01 00:00 [pmc-release]
AID - gut.2006.108613 [pii]
AID - gt108613 [pii]
AID - 10.1136/gut.2006.108613 [doi]
PST - ppublish
SO  - Gut. 2007 Sep;56(9):1291-5. doi: 10.1136/gut.2006.108613. Epub 2007 Mar 7.